BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 32917216)

  • 21. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
    Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
    Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Sekerci A; Turk HM; Demir T; Seker M; Akcakaya A; Arici DS
    J Coll Physicians Surg Pak; 2020 Aug; 30(8):863-867. PubMed ID: 32893801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy.
    Maekawa A; Kudo A; Kishino M; Murase Y; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Ogawa K; Ono H; Tanaka S; Kinowaki Y; Tanabe M
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):697-706. PubMed ID: 33904982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
    Delektorskaya VV; Kozlov NA; Chemeris GY
    Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Furukawa T; Ozaka M; Takamatsu M; Takazawa Y; Inamura K; Inoue Y; Mie T; Takeda T; Kanata R; Kasuga A; Matsuyama M; Sasaki T; Takahashi Y; Sasahira N
    Int J Surg Pathol; 2021 Aug; 29(5):475-481. PubMed ID: 33543658
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
    Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
    Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
    Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience.
    Akın Telli T; Esin E; Yalçın Ş
    Balkan Med J; 2020 Aug; 37(5):281-286. PubMed ID: 32573179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
    Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
    World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G3 GEP NENs category: are basic and clinical investigations well integrated?
    Milione M; Fazio N
    Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
    Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.